Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAB-3068 in advanced solid tumors
NCT03565003Phase 2Completed
- Sponsor
- Jacobio Pharmaceuticals
- Start
- Nov 2018
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of JAB-3068 in solid tumor, lymphoma, non-small cell lung cancer (NSCLC), Esophageal Squamous Cell Carcinoma (ESCC), head and neck squamous cell carcinoma (HNSCC), sponsored by Jacobio Pharmaceuticals. Started Nov 2018; status: completed.
02
Drugs
JAB-3068
03
Conditions
solid tumorlymphomanon-small cell lung cancer (NSCLC)Esophageal Squamous Cell Carcinoma (ESCC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03565003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03565003.